Optimum Investment Advisors lessened its holdings in shares of Synopsys, Inc. (NASDAQ:SNPS) by 25.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,200 shares of the semiconductor company’s stock after selling 1,100 shares during the period. Optimum Investment Advisors’ holdings in Synopsys were worth $439,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Next Capital Management LLC acquired a new position in shares of Synopsys during the 2nd quarter worth approximately $26,000. Ruggie Capital Group acquired a new position in shares of Synopsys during the 2nd quarter worth approximately $32,000. Virtus ETF Advisers LLC acquired a new position in Synopsys in the 2nd quarter valued at $34,000. Arcadia Investment Management Corp MI acquired a new position in Synopsys in the 2nd quarter valued at $42,000. Finally, Motco acquired a new position in Synopsys in the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 89.19% of the company’s stock.
SNPS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on Synopsys from $138.00 to $157.00 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Credit Suisse Group reiterated a “positive” rating and set a $150.00 target price (up from $125.00) on shares of Synopsys in a research report on Thursday, August 22nd. Zacks Investment Research upgraded Synopsys from a “sell” rating to a “hold” rating and set a $142.00 target price for the company in a research report on Monday, August 26th. ValuEngine downgraded Synopsys from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub downgraded Synopsys from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Synopsys currently has a consensus rating of “Buy” and a consensus price target of $145.64.
SNPS traded up $0.98 on Friday, reaching $136.21. The stock had a trading volume of 763,700 shares, compared to its average volume of 1,089,892. The company has a current ratio of 0.99, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $20.38 billion, a price-to-earnings ratio of 48.30, a price-to-earnings-growth ratio of 3.32 and a beta of 1.20. The firm has a 50-day moving average of $136.69 and a 200-day moving average of $130.73. Synopsys, Inc. has a fifty-two week low of $79.14 and a fifty-two week high of $146.66.
Synopsys (NASDAQ:SNPS) last posted its quarterly earnings results on Wednesday, August 21st. The semiconductor company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.03. The company had revenue of $853.00 million for the quarter, compared to the consensus estimate of $831.03 million. Synopsys had a return on equity of 16.56% and a net margin of 18.94%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.95 EPS. Sell-side analysts anticipate that Synopsys, Inc. will post 3.15 EPS for the current fiscal year.
Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits (ICs). It offers Fusion Design Platform, a digital design implementation solution; Verification Continuum Platform, which provides virtual prototyping, static and formal verification, simulation, emulation, field-programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.
Read More: How do taxes affect a CDs total return?
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.